Slit2在乳腺组织的表达与乳腺癌脑转移的关系

目的 检测神经轴突导向蛋白2(Slit2)在不同乳腺肿瘤组织中的表达,探讨Slit2与乳腺癌脑转移的相关性.方法 采用免疫组织化学LSAB法检测对24例发生脑转移的乳腺浸润性导管癌(IDC)、71例未发生脑转移的乳腺浸润性导管癌、22例乳腺导管内癌和23例乳腺腺纤维瘤组织中Slit2的表达.结果 Slit2在浸润性导管癌中有脑转移患者的阳性表达率(13%)明显低于无脑转移患者(59%)(P＜0.05);在乳腺导管内癌和浸润性导管癌中的阳性表达率(59%和48%)均明显低于乳腺纤维瘤(87%,P＜0.05);但前两者间差异无统计学意义(P＞0.05);在50岁以上乳腺癌患者中的阳性表达率(62%)明显高于50岁及以下患者(34%,P＜0.05);在生存期＜5年的乳腺浸润性导管癌患者组织中Slit2的阳性表达率(18%)明显低于生存期＞5年的患者(59%)(P＜0.05).Slit2阴性的患者总生存时间明显短于Slit2阳性患者(P＜0.01).Slit2在乳腺癌中的表达与肿瘤大小、淋巴结转移状态、病理学分期、组织学分级均无明显相关(P＞0.05).结论 乳腺癌中Slit2的表达和乳腺癌脑转移呈负相关,和乳腺浸润性导管癌患者的发病年龄及预后呈正相关,可成为判断乳腺癌预后和脑转移的分子标志物.

Slit2 Expression in breast cancer and its relationship to brain metastasis

Objective To detect the expression of Slit2 in breast tumors and its association with the breast cancer brain metastasis. Methods Immunohistochemistry staining was performed for Slit2 expression on specimens from 24 cases of invasive ductal carcinoma (IDC) with brain metastasis, 71 cases of IDC without brain metastasis, 22 cases of ductal carcinoma in situ (DCIS) and 23 cases of fibroadenoma.Results ( 1 ) The expression level of Slit2 in IDC with brain metastasis ( 13% ) was significantly lower than that in IDC without brain metastasis ( 59% ), P ＜ 0. 05. (2) The expression level of Slit2 in IDC (48%) and DCIS (59%) was significantly lower than that in adenofibroma (87%),P ＜0.05. The expression of Slit2 in IDC was lower than that in DCIS, but had no significant difference,P ＞ 0.05. (3) The expression of Slit2 was significantly higher in more than 50 year-old-group (62%) than that in less than 50 year-old-group (34%) of IDC patients, and highly related with the duration of IDC patients,P ＜0.05. No correlation was found between the Slit2 expression and the tumor size, lymph node metastasis, pathologic stage and histological grade, P ＞ 0.05. Conclusion The Slit2 expression correlates negatively with IDC brain metastasis, and positively with the age and duration of IDC patients. Slit2 could be applied as a marker in evaluating the IDC invasiveness and brain metastasis, and could be a new therapeutic target.